nach oben

CNS Drugs

Erschienen in:

01.12.2004 | Review Article

New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder

Therapeutic Potential

verfasst von: Dr Daniel F. Connor, Ronald J. Steingard

Erschienen in: CNS Drugs | Ausgabe 14/2004

Einloggen, um Zugang zu erhalten

Abstract

New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD.

While the therapeutic potential of immediate-release enantiomers of methyl-phenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Press, 1994

Barkley RA. International consensus statement on ADHD. Clin Child Fam Psychol Rev 2002; 5: 89–111PubMedCrossRef

Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107(3): e43PubMedCrossRef

Hinshaw SP. Attention deficits and hyperactivity in children. Thousand Oaks (CA): Sage, 1994

US Department of Health and Human Services. Mental health: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999

American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyper-activity disorder. Pediatrics 2001; 108: 1033–44CrossRef

Barkley RA. Attention-deficit hyperactivity disorder. Sci Am 1998; 279: 66–71PubMedCrossRef

Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry 1987; 44: 69–76PubMedCrossRef

Fergusson DM, Horwood LJ, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnoses in a birth cohort of 15 year olds. J Am Acad Child Adolesc Psychiatry 1993; 32: 1127–34PubMedCrossRef

10.

McGee R, Feehan M, Williams S, et al. DSM-III disorders in a large sample of adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 611–9PubMedCrossRef

11.

Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. Arch Gen Psychiatry 1988; 45: 1120–6PubMedCrossRef

12.

Rohde LA. ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131–3PubMedCrossRef

13.

Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716–22PubMedCrossRef

14.

Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629–38PubMedCrossRef

15.

Esser G, Schmidt MH, Woerner W. Epidemiology and course of psychiatric disorders in school-age children: results of a longitudinal study. J Child Psychol Psychiatry 1990; 31: 243–63PubMedCrossRef

16.

Bhatia MS, Nigam VR, Bohra N, et al. Attention deficit disorder with hyperactivity among paediatric outpatients. J Child Psychol Psychiatry 1991; 32: 297–306PubMedCrossRef

17.

Leung PWL, Luk SL, Ho TP, et al. The diagnosis and prevalence of hyperactivity in Chinese schoolboys. Br J Psychiatry 1996; 168: 486–96PubMedCrossRef

18.

Kanbayashi Y, Nakata Y, Fujii K, et al. ADHD-related behavior among non-referred children: parents’ ratings of DSM-III-R symptoms. Child Psychiatry Hum Dev 1994; 25: 13–29PubMedCrossRef

19.

Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry 2000; 39: 1520–7PubMedCrossRef

20.

Verhulst FC, van der Ende J, Ferdinand RF, et al. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 1997; 54: 329–36PubMedCrossRef

21.

Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279: 1100–7PubMedCrossRef

22.

Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59: 4–16PubMedCrossRef

23.

Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–32PubMedCrossRef

24.

Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792–8PubMed

25.

Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21–9PubMedCrossRef

26.

Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders: findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997; 6: 318–29PubMed

27.

Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking: findings from a high-risk sample of siblings. Am J Addict 1997; 6: 205–17PubMed

28.

Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 37–44PubMedCrossRef

29.

Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between maternal smoking during pregnancy and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998; 27: 352–8PubMedCrossRef

30.

Leibson C, Katusic S, Barbaresi W, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60–6PubMedCrossRef

31.

Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71–8PubMedCrossRef

32.

Bijur P, Golding J, Haslum M, et al. Behavioral predictors of injury in school-age children. Am J Dis Child 1988; 142: 1307–12PubMed

33.

Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996; 98: 1089–95PubMed

34.

Nader PE. School health: policy and practice. Elk Grove Village (IL): American Academy of Pediatrics, 1993

35.

American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36: 85–121SCrossRef

36.

Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904–21PubMedCrossRef

37.

Connor DF. Aggression and antisocial behavior in children and adolescents: research and treatment. New York: Guilford Press, 2002

38.

DuPaul GJ, Stoner G. ADHD in the schools: assessment and intervention strategies. New York: Guilford Press, 1994

39.

Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 77–97PubMed

40.

Elia J, Borcherding B, Rapoport J, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatr Res 1991; 36: 141–55CrossRef

41.

Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: e39PubMedCrossRef

42.

Multimodal Treatment of ADHD Group. Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088–96CrossRef

43.

Arnold LE. Methylphenidate vs amphetamine: comparative review. J Atten Disord 2000; 3: 200–11CrossRef

44.

Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304–13PubMedCrossRef

45.

Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857–64PubMedCrossRef

46.

Laufer MW, Denhoff E, Solomons G. Hyperkinetic impulse disorder in children’s behavior problems. Psychosom Med 1957; 19: 38–49PubMed

47.

Fischer M, Barkley RA, Smallish L, et al. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463–75PubMedCrossRef

48.

Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816–8PubMedCrossRef

49.

Biederman J, Milberger S, Faraone SV, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 1495–503PubMedCrossRef

50.

Jensen PS. ADHD: current concepts on etiology, pathophysiology, and neurobiology. Child Adolesc Psychiatr Clin N Am 2000; 9: 557–72PubMed

51.

Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 1991; 25: 277–83PubMedCrossRef

52.

Zametkin A, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998; 59: 17–23PubMed

53.

Posner MI, Raichle ME. Images of mind. Rev. ed. Washington, DC: Scientific American Books, 1996

54.

Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127–52PubMedCrossRef

55.

Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000; 9: 573–603PubMed

56.

Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264–72PubMedCrossRef

57.

Barkley RA, DuPaul GJ, Connor DF. Stimulants. In: Werry JS, Aman MG, editors. Practitioner’s guide to psychoactive drugs for children and adolescents. New York: Plenum Medical Book Company, 1999: 213–47

58.

Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951–8PubMedCrossRef

59.

Pliszka SR. Neuroscience for the mental health clinician. New York: Guilford Press, 2003: 279

60.

Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456–63PubMedCrossRef

61.

Wilens TE, Spencer TJ. Pharmacology of amphetamines. In: Tarter RE, Ammerman RT, Ott PJ, editors. Handbook of substance abuse neurobehavioral pharmacology. New York: Plenum Press, 1998: 501–13

62.

Diener RM. Toxicology of ritalin. In: Greenhill LL, Osman BB, editors. Ritalin theory and patient management. New York: Mary Ann Liebert Inc., 1991: 35–43

63.

Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987; 80: 491–501PubMed

64.

Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by doseresponse analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34: 1504–13PubMedCrossRef

65.

Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 199–248

66.

Caldwell J, Sever PS. The biochemical pharmacology of abused drugs. Clin Pharmacol Ther 1974; 16: 625–38PubMed

67.

Greenhill LL. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995; 4: 123–68

68.

Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989; 28: 768–72PubMedCrossRef

69.

Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002; 63: 656–7PubMedCrossRef

70.

Huang W, Gao Q, Harris M, et al. Separation of ritalin racemate and its by-product racemates by capillary electrophoresis. Electrophoresis 2001; 22: 3226–31PubMedCrossRef

71.

Ferris R, Tang F. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradol on the uptake of 1-[3H]-norepinephrine and [3H]-dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979; 210: 422–8PubMed

72.

Eckerman DA, Moy SS, Perkins AN, et al. Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 1991; 40: 875–80PubMedCrossRef

73.

Novartis Pharmaceuticals. Focalin product monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002: 5–19

74.

Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threomethylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131: 71–8CrossRef

75.

Srinivas NR, Hubbard JA, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methyl-phenidate in children with attention deficit disorder. Clin Pharmacol Ther 1992; 52: 561–8PubMedCrossRef

76.

Dexmethylphenidate (Focalin) for ADHD. The Medical Letter 2002; 44(1130): 45–6

77.

Safer DJ, Zito JM, Gardner JF. Pemoline hepatotocxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40: 622–9PubMedCrossRef

78.

McNeil Pharmaceuticals. Concerta product monograph. Fort Washington (PA): 2001: 2-28

79.

ALZA Technologies. Concerta™: a success story [online] Available from URL: http://www.alza.com/pdf/vol_1_1.pdf [Accessed 2004 Oct 1]. Delivery Times 2001; 1 (1)

80.

Data on file, Adderall XR. Shire US Inc., 2001

81.

Novartis Pharmaceuticals. Ritalin LA Product Monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002

82.

Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10: 2003–11PubMedCrossRef

83.

Faraone SV, Pliszka SR, Olvera RL, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol 2001; 11: 171–80PubMedCrossRef

84.

Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS Formulation). CNS Drugs 2001; 15: 495–500PubMedCrossRef

85.

Auiler JF, Liu JM, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFE) study. Curr Med Res Opin 2002; 18: 311–6PubMedCrossRef

86.

Pentikis HS, Simmons RD, Benedict MF, et al. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002; 41: 443–9PubMedCrossRef

87.

Michaels MA, Weston IE, Zhang Y, et al. Pharmacokinetics of SLI381, a two-component extended-release formulation of mixed amphetamine salts, administered in fasted and fed states, and sprinkled on food. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2001 May 29

88.

Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: 1–15CrossRef

89.

Wolraich ML, Greenhill LL, Pelham WE, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883–92PubMedCrossRef

90.

Swanson JM, Wigal SB, Lerner MA, et al. Comparison of the efficacy and safety of OROS methylphenidate HCL with methylphenidate tid and placebo in children with ADHD [abstract]. Pediatr Res 2000; 47: 199

91.

Wilens T, Pelham WE, Stein MT, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003; 42: 424–33PubMedCrossRef

92.

McCracken JT, McGough JJ, Biederman J, et al. Analogue classroom assessment of SLI381 for the treatment of ADHD [presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2000 Oct, New York

93.

Biederman J, Lopez F, Boellner S, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110: 258–66PubMedCrossRef

94.

Biederman J, Lopez F, Boellner S, et al. A randomized controlled trial of once-daily-dosed Adderall XR for the treatment of ADHD. Boston (MA): US Psychiatric and Mental Health Congress, 2001 Nov

95.

Ambrosini PJ, Lopez F, Chandler M, et al. An open-label community assessment trial of Adderall XR in pediatric ADHD [presentation]. 155^th Annual Meeting of the American Psychiatric Association; Philadelphia (PA); 2002 May 22

96.

Celltech Development. Protocol No. 1001-02. Wayne (PA): Celltech Development, 2002

97.

Boellner S, Tulloch SJ, Zhang Y. A single-dose bioequivalence study comparing 1 × 30mg capsule of SLI 381 to 3 × 10mg capsules of SLI 381 in pediatric subjects. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2002 May 29

98.

Swanson JM, Greenhill LL, Pelham WE, et al. Initiating Concerta (OROS methylphenidate HCL) qd in children with attention-deficit/hyperactivity disorder. J Clin Res 2000; 3: 59–76

99.

James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 1268–76PubMedCrossRef

100.

Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics 2001; 108: 1–9CrossRef

101.

Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475–82PubMedCrossRef

102.

Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug abuse? A 13-year prospective study. Pediatrics 2003; 111: 97–109PubMedCrossRef

103.

Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 11: 179–85CrossRef

104.

Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7: 156–63PubMed

Titel: New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder
Therapeutic Potential
verfasst von: Dr Daniel F. Connor
Ronald J. Steingard
Publikationsdatum: 01.12.2004
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 14/2004
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200418140-00005

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2004

The Role of Creatine in the Management of Amyotrophic Lateral Sclerosis and Other Neurodegenerative Disorders

Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents

Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Acute Ischaemic Stroke

The Role of Stimulants in the Treatment of Preschool Children with Attention-Deficit Hyperactivity Disorder

Obsessive-Compulsive Disorder in Schizophrenia